



Unlocking the Potential of Cannabinoid Medicines

Exchange:	TSX: IN	OTCQX: IMLFF
Share Price (09/03/19):	C\$0.43	\$0.32
Market Capitalization (09/03/19):	C\$73.2M	\$55.1M

Company Highlights

InMed is a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as an R&D pipeline of medications targeting diseases with high unmet medical needs.

Researching the therapeutic potential of rare cannabinoids, beyond THC & CBD

Developing a biosynthetic manufacturing approach that targets production of cannabinoids that are biologically identical to those produced by the plant

Select innovative, topically applied cannabinoid therapies for serious diseases with high unmet medical needs

Cannabinoids


Beyond the two most well-known cannabinoids THC and CBD, the human body's endocannabinoid receptors are predisposed to interact with the more than 100 other cannabinoids that have potential therapeutic properties. Many of these cannabinoids have been neglected as targets for scientific research because they are found in extremely low concentrations in the cannabis plant.

InMed is developing novel, non-THC, topically applied cannabinoid-based treatments of diseases with high unmet medical needs.

Biosynthesis

Proprietary biosynthesis program will allow InMed, and potentially other companies, through commercial partnerships, to access cannabinoids that are found in very limited amounts in the plant. These cannabinoids (i.e. "rare cannabinoids") may hold significant potential to treat human diseases.

This potentially industry-disruptive cannabinoid manufacturing process may offer several advantages over traditional methods (extraction from plants and chemical synthesis):



Of the extensive spectrum of potential diseases, InMed's initial two target indications address total market size of **>\$7.2B**

Significant cost & time savings vs existing growing / harvesting / extraction / purification methods

Access to rare cannabinoids that are currently economically unfeasible via plant extraction

Enhanced production, purification and quality control vs naturally-sourced products

Increased structural integrity vs chemical manufacturing methods

Clinical Pipeline

	INM-755	INM-088
Therapeutic Area	Epidermolysis Bullosa	Glaucoma
Addressable Patient Population	10.1K	14.2M
Total Market Size	\$1.0B	\$6.2B

Strong Intellectual Property Strategy

Filed several **Patent Cooperation Treaty (PCT) and provisional patent applications** to protect our inventions. Recent **patent applications** include:

2019: Expression of cannabinoid synthases in *E.coli*; precursor upregulation for cannabinoid production in *E.coli*

2019: Biosynthesis technology for the manufacturing of pharmaceutical-grade cannabinoids

2018: INM-405 program and other unique compositions as cannabinoid-based topical therapies for the treatment of pain

2018: Proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature

2018: INM-085, a cannabinoid-based topical therapy for glaucoma

2017: Cannabinoid-based topical therapy for diseases and conditions associated with Intermediate Filament Dysfunction (i.e. EB)

2017: INM-755 as a cannabinoid-based topical therapy for EB Simplex

INM-755 Epidermolysis Bullosa (“EB”)

- Group of genetic conditions causing skin to be very fragile and blister / rupture easily in response to minor injury or friction, such as rubbing or scratching
- INM-755 being investigated to deliver symptomatic relief in all EB patients via multiple potential mechanisms:
 - ✓ accelerated wound healing
 - ✓ pain reduction
 - ✓ itch reduction
 - ✓ reduce inflammation
 - ✓ antimicrobial activity
- May be further evaluated for its ability to strengthen skin (reduce the frequency of blistering) in a subset of EB patients

INM-088 Glaucoma

Target Effects

- Targeted to reduce the intraocular pressure (IOP) in the affected eyes
- Targeted to provide neuroprotection for the retinal ganglion (RGCs) and other optic nerve tissues in the affected eyes

Optimizing Delivery System

- Testing several nanoparticle carrier systems to optimize drug delivery and improve patient compliance
- Preclinical studies planning in 2H19 to demonstrate target effects



Recent News

Aug. 2, 2019

- ✓ Appointed Bruce S. Colwill, CPA, CA as Chief Financial Officer and Announced other Leadership Changes

Jul. 2, 2019

- ✓ Appointed Catherine Sazdanoff, JD, to Board of Directors

May 15, 2019

- ✓ Reported Third Quarter Fiscal 2019 Financial Results and Provided R&D and Business Update

Mar. 18, 2019

- ✓ Announced Strengthened IP Portfolio for Biosynthesis Platform Technology

Mar. 13, 2019

- ✓ Announced Transition to Single Cannabinoid Investigational Drug Candidate – INM-755 – for Epidermolysis Bullosa Program

Development Targets

- INM-755**
 - ✓ **1Q19:** Finalized formulation for INM-755
 - 2H19:** Submit Clinical Trial Application
 - 2H19:** Initiate Phase 1 clinical trial in the Netherlands
 - 2H20:** File for Phase 1/2a in EB patients
- INM-088**
 - 2H19:** Initiate additional preclinical *in vivo* studies
 - 1H20:** Optimize formulation and delivery technology
 - 1H20:** Request pre-IND meeting with regulatory authorities
 - 1H20:** Initiate IND enabling studies

Management Team

Eric A. Adams, MIBS Chief Executive Officer

25+ years experience in global biopharma leadership, business development, sales, marketing, M&A with enGene, QLT, Abbott, Fresenius.

Bruce S. Colwill, CPA, CA Chief Financial Officer

25+ years financial experience in both public and private companies, spanning the cleantech, resources, biotech, and technology sectors.

Alexandra D.J. Mancini, MSc SVP, Clinical and Regulatory Affairs

30+ years experience in global biopharmaceutical R&D with numerous biotech companies, including Sirius Genomics, Inex Pharmaceuticals, and QLT.

Dr. Eric C. Hsu, PhD SVP, Preclinical R&D

18+ years scientific leadership experience with enGene Inc. in novel gene transfer technologies, formulation development and process development.

Michael Woudenberg, P.Eng. VP, Chemistry, Manufacturing & Controls

20+ years experience in engineering, leadership and GMP manufacturing and scale up at 3M, Cardiome Pharma, Arbutus Biopharma, and Phyton Biotech.

Jeff Charpentier, CPA, CA VP, Finance

25+ years financial experience in biotech and tech companies, including Lifebank Corp., Inex Pharmaceuticals, and Chromos Molecular Systems.



Investor Relations Contacts

Bruce Colwill
InMed Pharma, CFO
+1.604.669.7207
info@inmedpharma.com

Joe Green
Edison Advisors
+1.646.653.7035
jgreen@edisongroup.com

Financials

TSX: IN (as of 08/29/19)
Shares Outstanding: 172.3M
Options/Warrants: 38.6M
Diluted Shares: 210.9M
Cash/C.E. & S.T.-I. at 03/31/19: C\$20.3M